hrcak mascot   Srce   HID

Pregledni rad

Effects of Tamoxifen on the female genital tract

Mario Puljiz ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Damir Danolić ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Ilija Alvir ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Ivica Mamić ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia

Puni tekst: engleski, pdf (141 KB) str. 61-64 preuzimanja: 198* citiraj
APA 6th Edition
Puljiz, M., Danolić, D., Alvir, I. i Mamić, I. (2014). Effects of Tamoxifen on the female genital tract. Libri Oncologici, 42 (1-3), 61-64. Preuzeto s https://hrcak.srce.hr/199080
MLA 8th Edition
Puljiz, Mario, et al. "Effects of Tamoxifen on the female genital tract." Libri Oncologici, vol. 42, br. 1-3, 2014, str. 61-64. https://hrcak.srce.hr/199080. Citirano 27.01.2021.
Chicago 17th Edition
Puljiz, Mario, Damir Danolić, Ilija Alvir i Ivica Mamić. "Effects of Tamoxifen on the female genital tract." Libri Oncologici 42, br. 1-3 (2014): 61-64. https://hrcak.srce.hr/199080
Harvard
Puljiz, M., et al. (2014). 'Effects of Tamoxifen on the female genital tract', Libri Oncologici, 42(1-3), str. 61-64. Preuzeto s: https://hrcak.srce.hr/199080 (Datum pristupa: 27.01.2021.)
Vancouver
Puljiz M, Danolić D, Alvir I, Mamić I. Effects of Tamoxifen on the female genital tract. Libri Oncologici [Internet]. 2014 [pristupljeno 27.01.2021.];42(1-3):61-64. Dostupno na: https://hrcak.srce.hr/199080
IEEE
M. Puljiz, D. Danolić, I. Alvir i I. Mamić, "Effects of Tamoxifen on the female genital tract", Libri Oncologici, vol.42, br. 1-3, str. 61-64, 2014. [Online]. Dostupno na: https://hrcak.srce.hr/199080. [Citirano: 27.01.2021.]

Sažetak
Tamoxifen, a triphenylethyleneestrogen receptor modulator, is an eff ective treatment for estrogen receptor positive breast cancer patients. It acts as an estrogen antagonist in breast tissue and a week estrogen agonist in the female genital tract. Its estrogenagonist properties refl ects on increased risk of gynaecologic pathologies and includes the development of
endometrial cancer, endometrial hyperplasia, endometrial polyps, adenomyosis, leiomyomas, uterine sarcomas, cervical polyps and ovarian cysts. Breast cancer patients during tamoxifen treatment should be under close gynaecological and ultrasonographic surveillance.

Ključne riječi
tamoxifen; breast cancer; female genital tract; endometrial cancer

Hrčak ID: 199080

URI
https://hrcak.srce.hr/199080

[hrvatski]

Posjeta: 276 *